⌕
Braveheart Bio · BRVE · Nasdaq
Tenet — · insufficient data
Compare
$19.49−0.66%At close
$19.49−0.13 (−0.66%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Braveheart Bio (BRVE) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is BRVE's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● GlobeNewsWireNov 10, 2026 · 16:03 ETCOMPANY'S OWN WORDS
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893's potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen LIONHEART-HCM oHCM Pha…

BRVE −0.7% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London

SAN FRANCISCO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other ser…

BRVE −0.7% todayRead at source ↗
● Seeking AlphaNov 6, 2026 · 22:04 ET
Braveheart Bio, Inc. (BRVE) Shareholder/Analyst Call Transcript

Braveheart Bio, Inc. (BRVE) Shareholder/Analyst Call Transcript…

BRVE −0.7% todayRead at source ↗
● MarketBeatNov 6, 2026 · 20:16 ET
Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial

Braveheart Bio NASDAQ: BRVE presented one-year data from a small study of its experimental heart drug BHB-1893 and outlined plans for a fixed-dose trial, as the company advances the treatment through late-stage developme…

BRVE −0.7% todayRead at source ↗
● GlobeNewsWireNov 6, 2026 · 15:15 ET
Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026

HRS/BHB-1893 demonstrated meaningful improvements in exercise capacity and patient-reported outcomes, with rapid, deep, and durable left ventricular outflow tract (LVOT) gradient reduction at 52 weeks…

BRVE −0.7% todayRead at source ↗
● GlobeNewsWireOct 30, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026

SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other ser…

BRVE −0.7% todayRead at source ↗
● GlobeNewsWireOct 30, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026

SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other ser…

BRVE −0.7% todayRead at source ↗
● Seeking AlphaOct 20, 2026 · 08:55 ET
Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product

Braveheart Bio is undervalued as a late-stage HCM player, with two Phase 3 programs fully funded and a differentiated molecule for non-obstructive HCM. BRVE holds $527M in pro forma cash, supporting operations into 2029 …

BRVE −0.7% todayRead at source ↗
● Defense WorldOct 2, 2026 · 06:41 ET
Braveheart Bio (NASDAQ:BRVE) Stock Falls 7.3% – Here’s What Happened

Shares of Braveheart Bio, Inc. (NASDAQ: BRVE - Get Free Report) were down 7.3% during mid-day trading on Wednesday. The stock traded as low as $20.86 and last traded at $20.7090. 36,478 shares were traded during mid-day …

BRVE −0.7% todayRead at source ↗
● GlobeNewsWireSep 16, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Braveheart Bio to Participate in Stifel Cardiometabolic Forum

SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other se…

BRVE −0.7% todayRead at source ↗
● GlobeNewsWireSep 8, 2026 · 16:03 ETCOMPANY'S OWN WORDS
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effect to Braveheart Bio…

BRVE −0.7% todayRead at source ↗
● GlobeNewsWireSep 1, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Braveheart Bio to Participate in Cantor Global Healthcare Conference

SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other se…

BRVE −0.7% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA7−4.1%

Article counts from the last market-wide feed page, across every symbol we track and not just BRVE · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.